82 results
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
on the ClinicalTrials.gov data registry. Information related to the product, patient population, phase of investigation, study sites and investigators and other … pediatric investigation plan, the authorized product information includes information on the results of the studies and the product is authorized in all
8-K
EX-10.2
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether … .
(j) Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company
8-K
EX-10.1
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
to Nasdaq delisting, which have been disclosed in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court … be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received and payment therefor
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
5 Aug 24
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
8:15am
success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Jul 24
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
9:00am
, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered
S-1/A
xunyultm t71e7
17 Jul 24
IPO registration (amended)
8:47am
S-1/A
EX-10.9
fu651kpufk8 gz1wr05
17 Jul 24
IPO registration (amended)
8:47am
S-1
2fauvqp eb
3 Jul 24
IPO registration
6:29am
8-K
EX-99.1
5nu8ax
30 May 24
Other Events
8:30am
8-K
EX-99.1
bcrs tp57
7 May 24
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
8:30am
8-K
EX-99.1
u537ev3fim7yvn7zl
16 Apr 24
Incannex Healthcare Inc. Quarterly Update, Q1 2024
9:30am
8-K
EX-99.1
ytdsid r8b8rxubu
28 Feb 24
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
7:42am
8-K
EX-99.1
xxxi0sj6rx06ueqiyrqv
16 Feb 24
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
8:00am
8-K
EX-99.1
wk3l7ody
1 Feb 24
Other Events
7:30am
8-K
EX-99.1
cpfu9jn7qa676j
24 Jan 24
Other Events
4:30pm
8-K
EX-99.1
ofsg 4306a2pdh
18 Jan 24
Other Events
9:08am
8-K
EX-99.1
op4g71
17 Jan 24
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
6:05am
8-K
EX-99.1
ct3f64wm0ndolqq2eev
22 Dec 23
Clarion Clinics Receives Ethics Board Endorsment for the First Dedicated Psychedelic-assisted Therapy Clinic In Australia
6:07am
S-8
EX-5.1
jfm4f
20 Dec 23
Registration of securities for employees
5:05pm
S-8
o3souceje
20 Dec 23
Registration of securities for employees
5:05pm